Haleos Labs Limi

{
  "main_header": {
    "sid": 1002809,
    "name": "Haleos Labs Limi",
    "stock_name": "Haleos Labs Limi",
    "full_name": "Haleos Labs Limited",
    "name_url": "stocks-analysis/haleos-labs-limi",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,272.00",
    "chg": -22.65,
    "chgp": "-1.75%",
    "dir": -1,
    "prev_price": "1,294.65",
    "mcapval": "393.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540679,
    "symbol": "HALEOSLABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE320X01016",
    "curr_date": "Mar 05",
    "curr_time": "",
    "bse_nse_vol": "11.27 k",
    "exc_status": "Active",
    "traded_date": "Mar 05, 2026",
    "traded_date_str": "2026 03 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/haleos-labs-limi-1002809-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Haleos Labs Limited Upgraded to Hold as Technicals Improve and Valuation Attracts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-upgraded-to-hold-as-technicals-improve-and-valuation-attracts-3872894",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/HaleosLabsLimit_mojoScore_3872894.png",
        "date": "2026-03-05 08:31:10",
        "description": "Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 4 March 2026. This revision reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, signalling a cautious but more optimistic outlook for investors amid mixed fundamental signals."
      },
      {
        "title": "Haleos Labs Limited is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-sell-3857770",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/HaleosLabsLimit_mojoScore_3857770.png",
        "date": "2026-02-26 10:10:50",
        "description": "Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Haleos Labs Limited is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-by-marketsmojo-3839063",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/HaleosLabsLimit_mojoScore_3839063.png",
        "date": "2026-02-14 10:10:31",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Are Haleos Labs Limited latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-haleos-labs-limited-latest-results-good-or-bad-3835929",
        "imagepath": "",
        "date": "2026-02-12 20:02:58",
        "description": "Haleos Labs Limited's latest financial results for Q3 FY26 reveal a complex operational landscape characterized by robust revenue growth alongside margin pressures. The company achieved net sales of ₹94.78 crores, marking a year-on-year increase of 12.03% from ₹84.60 crores in Q3 FY25. This performance represents the highest quarterly revenue in the company's history and signifies a sequential growth of 16.48% from the previous quarter, indicating strong market demand and potential successful product launches.\n\nHowever, the profitability metrics present a more nuanced picture. The net profit for the quarter reached ₹6.62 crores, reflecting a year-on-year growth of 21.02% compared to ₹5.47 crores in Q3 FY25. Despite this positive trajectory in profit, the operating margin contracted to 14.82%, down from 16.69% in the prior quarter, indicating rising cost pressures that are absorbing some of the revenue gains..."
      },
      {
        "title": "Haleos Labs Q3 FY26: Strong Quarter Drives Margin Recovery Despite Sector Headwinds",
        "link": "https://www.marketsmojo.com/news/result-analysis/haleos-labs-q3-fy26-strong-quarter-drives-margin-recovery-despite-sector-headwinds-3835266",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/HaleosLabsLimit_quaterlyResult_3835266.png",
        "date": "2026-02-12 09:53:56",
        "description": "Haleos Labs Limited (NSE: HALEOSLABS), a micro-cap pharmaceutical company with a market capitalisation of ₹379.42 crores, delivered its strongest quarterly performance in Q3 FY26 (October-December 2025), posting consolidated net profit of ₹6.62 crores—an 8.52% quarter-on-quarter increase and a robust 21.02% year-on-year growth. The Hyderabad-based company, which operates in the highly competitive pharmaceuticals and biotechnology sector, saw its stock trading at ₹1,255.00 as of February 12, 2026, down 1.27% on the day but reflecting a complex narrative of operational improvement amidst valuation concerns."
      },
      {
        "title": "When is the next results date for Haleos Labs Limited?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-haleos-labs-limited-3823252",
        "imagepath": "",
        "date": "2026-02-05 23:18:32",
        "description": "Haleos Labs Limited is scheduled to declare its results on 11 February 2026...."
      },
      {
        "title": "Haleos Labs Limited Upgraded to Hold by MarketsMOJO on Improved Technicals and Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-upgraded-to-hold-by-marketsmojo-on-improved-technicals-and-financials-3817395",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/HaleosLabsLimit_mojoScore_3817395.png",
        "date": "2026-02-03 08:21:02",
        "description": "Haleos Labs Limited has seen its investment rating upgraded from Sell to Hold as of 2 February 2026, reflecting a notable improvement in its technical indicators and valuation metrics. Despite lingering concerns over long-term fundamentals, recent quarterly financial performance and a shift in market sentiment have contributed to a more balanced outlook for this pharmaceuticals and biotechnology company."
      },
      {
        "title": "Haleos Labs Limited Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-upper-circuit-amid-strong-buying-pressure-3814729",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/HaleosLabsLimit_stocks_hitting_upper_circuit_3814729.png",
        "date": "2026-02-01 14:00:10",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 1 Feb 2026, closing at ₹1240.0, marking a maximum daily gain of 4.91%. This sharp rally was driven by robust buying interest despite subdued trading volumes and a regulatory freeze on further price movement, reflecting strong investor sentiment amid sector headwinds."
      },
      {
        "title": "Haleos Labs Limited is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-3804016",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/HaleosLabsLimit_mojoScore_3804016.png",
        "date": "2026-01-25 10:10:30",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 432,
    "sid": "1002809",
    "stock_news_url": "https://www.marketsmojo.com/news/haleos-labs-limited-1002809"
  },
  "announcements": [
    {
      "caption": "Special Window (Physical Shares)",
      "datetime": "28-Feb-2026",
      "details": "Special Window for the relodgment of share transfer requests in physical mode.",
      "source": "BSE"
    },
    {
      "caption": "Newspaper Publication (Financial Results)",
      "datetime": "13-Feb-2026",
      "details": "Enclosed - Newspaper advertisement",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Meeting Held On February 11 2026",
      "datetime": "11-Feb-2026",
      "details": "Enclosed - Outcome of 96th Board meeting.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Haleos Labs Limited has declared <strong>15%</strong> dividend, ex-date: 24 Sep 25",
          "dt": "2025-09-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Haleos Labs Limited Upgraded to Hold as Technicals Improve and Valuation Attracts

2026-03-05 08:31:10

Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 4 March 2026. This revision reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, signalling a cautious but more optimistic outlook for investors amid mixed fundamental signals.

Read full news article

Haleos Labs Limited is Rated Sell

2026-02-26 10:10:50

Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Read full news article

Haleos Labs Limited is Rated Hold by MarketsMOJO

2026-02-14 10:10:31

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Are Haleos Labs Limited latest results good or bad?

2026-02-12 20:02:58

Haleos Labs Limited's latest financial results for Q3 FY26 reveal a complex operational landscape characterized by robust revenue growth alongside margin pressures. The company achieved net sales of ₹94.78 crores, marking a year-on-year increase of 12.03% from ₹84.60 crores in Q3 FY25. This performance represents the highest quarterly revenue in the company's history and signifies a sequential growth of 16.48% from the previous quarter, indicating strong market demand and potential successful product launches. However, the profitability metrics present a more nuanced picture. The net profit for the quarter reached ₹6.62 crores, reflecting a year-on-year growth of 21.02% compared to ₹5.47 crores in Q3 FY25. Despite this positive trajectory in profit, the operating margin contracted to 14.82%, down from 16.69% in the prior quarter, indicating rising cost pressures that are absorbing some of the revenue gains...

Read full news article

Haleos Labs Q3 FY26: Strong Quarter Drives Margin Recovery Despite Sector Headwinds

2026-02-12 09:53:56

Haleos Labs Limited (NSE: HALEOSLABS), a micro-cap pharmaceutical company with a market capitalisation of ₹379.42 crores, delivered its strongest quarterly performance in Q3 FY26 (October-December 2025), posting consolidated net profit of ₹6.62 crores—an 8.52% quarter-on-quarter increase and a robust 21.02% year-on-year growth. The Hyderabad-based company, which operates in the highly competitive pharmaceuticals and biotechnology sector, saw its stock trading at ₹1,255.00 as of February 12, 2026, down 1.27% on the day but reflecting a complex narrative of operational improvement amidst valuation concerns.

Read full news article

When is the next results date for Haleos Labs Limited?

2026-02-05 23:18:32

Haleos Labs Limited is scheduled to declare its results on 11 February 2026....

Read full news article

Haleos Labs Limited Upgraded to Hold by MarketsMOJO on Improved Technicals and Financials

2026-02-03 08:21:02

Haleos Labs Limited has seen its investment rating upgraded from Sell to Hold as of 2 February 2026, reflecting a notable improvement in its technical indicators and valuation metrics. Despite lingering concerns over long-term fundamentals, recent quarterly financial performance and a shift in market sentiment have contributed to a more balanced outlook for this pharmaceuticals and biotechnology company.

Read full news article

Haleos Labs Limited Hits Upper Circuit Amid Strong Buying Pressure

2026-02-01 14:00:10

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 1 Feb 2026, closing at ₹1240.0, marking a maximum daily gain of 4.91%. This sharp rally was driven by robust buying interest despite subdued trading volumes and a regulatory freeze on further price movement, reflecting strong investor sentiment amid sector headwinds.

Read full news article

Haleos Labs Limited is Rated Hold

2026-01-25 10:10:30

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News